A research project
A daily stock screen, and a coach for how you trade it.
Thirty screens, five index universes, published every morning — with the four technical gates and the honest entry date.
Then the part that matters: the agent learns how you actually trade — your sizing, your timing, your costs — and tells you straight. Your account stays with your broker.
Daily Portfolio
An AI-built portfolio lands in your inbox each morning, before the market opens. Holdings ranked by conviction, weights by risk.
AI Agent
Screen assets, build portfolios, manage risk, and execute trades through natural conversation — no quant expertise needed.
Technical Screener
Four-gate screening across momentum, breakouts, implied volatility, and volume — on any ticker or your existing holdings.
Risk Management
Weatherproofing, regime detection, position sizing, and trailing stops built into every recommendation.
Thousands of strategy configurations. Every day. The top performers build tomorrow’s portfolio.
The platform analyzes millions of daily trading strategy combinations using AI and quantitative research, automatically aggregating winners to build and deliver pre-optimized daily portfolios every morning. Subscribers get access to automated portfolio generation, an interactive dashboard, a Technical Screener, and an AI agent that helps manage risk, execute trades, weatherproof portfolios, provide insights, and learn from trading patterns.
Origin
Goldflower was founded and funded by George Dikos, drawing on more than a decade of independent proprietary research. The name pays tribute to Chrysanthi — Greek for ‘golden flower’ — a beloved name in the Dikos family, in the tradition of Greek seafarers who name their vessels after those closest to them.
A pledge of trust.
Research, not advice
Goldflower is an independent research project. Nothing you read here is investment advice. We show you what the model finds; you decide what to do with it.
Your data, nothing more
We collect your email address to send the daily digest. That is all. We do not sell it, profile it, or share it with anyone.
Evidence you can check
We publish the research behind the screens, not just their output, including a matched comparison against similar stocks. The evidence page has the figures; you draw your own conclusion.
Free during research
The platform is free during the research phase. If that changes, subscribers are notified with enough lead time to decide. No surprise charges, ever.